This 2-day CME-event will review the latest advances in lung cancer focused on what a medical oncologist needs to know to provide state-of-the-art care today.
Advocate for the change you want to see at the TxSCO 2023 Leadership Day! As an oncology professional who experiences the challenges of providing quality cancer care, you are best positioned to educate decision-makers on how coverage and reimbursement issues affect community oncology. Meeting face-to-face with legislators is the most effective way to share concerns, however, you may be reluctant to speak with policymakers, or have not been given the opportunity to do so.
That’s why we hope you will join us for this inspirational day of sharing your patients’ stories at the Texas State Capitol.
Not a policy expert? No problem! Our experts will provide talking points to prepare you for your meetings with policymakers!
Wednesday, February 8, 2023 | 5:00 - 8:00 PM
Registration, Welcome Dinner, Sessions
Thursday, February 9, 2023 | 7:30 AM – 2:00 PM
Registration, Legislative Visits, Lunch (at hotel)
If you are employed by a pharmaceutical/device manufacturer, consulting, or technology company, please click on the “Industry Registration” button below for information.
REGISTER INDUSTRY REGISTRATION
Omni Austin Hotel Downtown
700 San Jacinto at 8th Street
Austin, TX 78701
512.476.3700
Parking:
Daily valet parking is available for $25.00/day
There is no room block associated with this conference. If you would like to make a reservation, please contact the hotel directly.
"TxSCO Leadership Day is a great opportunity to advocate and educate through meaningful discussions with legislators and their staff." -Todd Pickard, MMSc, PA-C, DFAAPA, FASCO, Executive Director Advanced Practice, University of Texas MD Anderson Cancer Center
Thu, March 30 to Sat, April 1, 2023 Austin, TX
ACL Live at the Moody Theater
310 W. 2nd Street
Austin, TX 78701
877.471.4225
Managing lung cancer has become increasingly complicated – reflecting the transformative benefits we see with immunotherapy and targeted therapy. Learn the best way to deliver these drugs from the very investigators leading the research.
This two-day CME-event will review the latest advances in lung cancer focused on what a medical oncologist needs to know to provide state-of-the-art care today. Featured speaker and TxSCO President Debra Patt, MD, PhD, MBA, FASCO, will share the latest on healthcare policy, while expert faculty will cover the basics (”What is NGS?”) and the advanced (“How can we predict and prevent acquired resistance?”) making this conference appropriate for all levels of training and experience.
As one benefit of membership, TxSCO members can take advantage of the following discounted registration rates:
Early Bird - Until January 29, 2023
$350 (nonmember rate: $450)
Registration
$450 (nonmember rate: $600)
On-Site Registration
$500 (nonmember rate: $700)
Details and Registration
Not a member? Join today and take advantage of this exclusive opportunity!
The W Hotel
200 Lavaca St.
Austin, TX 78701
866.961.3327 or 512.542.3600
Hotel accommodations as well as additional conference activities will be held at The W Hotel located adjacent to ACL Live by a connecting walkway. Please contact The W directly to reserve your room and receive the TLC special group rate. The group rate will be honored until the contracted block of rooms has been sold out or until the cut-off date (March 8, 2023) has expired, whichever occurs first. For reservations, click here.
This event is presented by: IDEOlogy Health
Husain Evaluates Real-World Evidence for Immunotherapy in Stage III NSCLC
February 24th 2024During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Hatim Husain, MD, explained the significance of the PACIFIC trial and its real-world counterpart PACIFIC-R looking at the use of durvalumab after chemotherapy and radiation in patients with unresectable stage III non–small cell lung cancer.
Read More
Konduri Discusses Data Behind Treatment of KRAS G12C–Harboring NSCLC
June 29th 2023In the first of a 2-part article series, Kartik Konduri, MD, discusses the data behind the use of adagrasib and sotorasib for patients with advanced non–small cell lung cancer harboring a KRAS G12C mutation.
Read More